doxorubicin (P-Esbp-DOX) / Vaxil Bio - LARVOL DELTA

Dr Bilusic on Updates to the Urothelial Carcinoma Treatment Armamentarium (OncLive) - "Marijo Bilusic, MD, PhD, discusses updates seen in the treatment armamentarium for patients with urothelial carcinoma, as presented at the 2023 Sylvester Annual Oncology Updates Meeting."

Video

TTI-621 with Doxorubicin Trial

Live event

Vaxil Provides Update on Research Activities (GlobeNewswire) - "Vaxil...reported therapeutic success of P-Esbp-DOX, a novel anti-cancer drug, when tested in vivo in a mouse model of aggressive liver metastasis of colorectal cancer (CRC). P-Esbp-DOX was developed by Prof. Ayelet David, Head of the Drug Targeting and Nanomedicine Laboratory, Department of Clinical Biochemistry and Pharmacology from Ben-Gurion University of the Negev, for which Vaxil has a worldwide exclusive license. Following the promising results of the in vivo study, Vaxil is in the midst of a screening process of contract development and manufacturing companies for the development of P-Esbp-DOX to be used in a first in-human clinical trial."

Commercial • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor